Cadila Healthcare, one of the leading pharmaceutical companies, witnessed a rise in share price on Friday after it announced that the company has purchased 50% shares of Zydus BSV Pharma from Bharat Serums and Vaccines and now Zydus BSV has become 100% subsidiary of Cadila Healthcare.

Recently Zydus launched SoviHep, the breakthrough therapy for Hepatitis C in alliance with Gilead Sciences.

Shares of the comapny are trading at Rs 1,685.15, up Rs 23.9, or 1.44% at the Bombay Stock Exchange (BSE) on Friday at 10:22 a.m.

The scrip has touched an intra-day high of Rs 1,721.00 and low of Rs 1,679.75. The total volume of shares traded at the BSE is 8,114.